160 related articles for article (PubMed ID: 17980746)
1. Bevacizumab and retinal ischemia.
Neubauer AS; Kook D; Haritoglou C; Priglinger SG; Kampik A; Ulbig MW; Ceklic L
Ophthalmology; 2007 Nov; 114(11):2096. PubMed ID: 17980746
[No Abstract] [Full Text] [Related]
2. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME).
Querques G
Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285
[No Abstract] [Full Text] [Related]
3. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
4. Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema.
Chung EJ; Roh MI; Kwon OW; Koh HJ
Retina; 2008; 28(7):957-63. PubMed ID: 18698297
[TBL] [Abstract][Full Text] [Related]
5. The article by Kovach and Rosenfeld.
Charbel Issa P; Holz FG; Scholl HP
Retina; 2009 May; 29(5):717; author reply 717-8. PubMed ID: 19430284
[No Abstract] [Full Text] [Related]
6. Bevacizumab and macular edema.
Kumar A
Ophthalmology; 2008 Mar; 115(3):585. PubMed ID: 18319106
[No Abstract] [Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
8. Management of Coats disease with bevacizumab in 2 patients.
Venkatesh P; Mandal S; Garg S
Can J Ophthalmol; 2008 Apr; 43(2):245-6. PubMed ID: 18347637
[No Abstract] [Full Text] [Related]
9. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.
Kovach JL; Rosenfeld PJ
Retina; 2009 Jan; 29(1):27-32. PubMed ID: 18936721
[TBL] [Abstract][Full Text] [Related]
10. Comment of article by Matsumoto Y.
Campa C; D'Angelo S; Incorvaia C
Retina; 2008 May; 28(5):782; author reply 782-3. PubMed ID: 18463528
[No Abstract] [Full Text] [Related]
11. Diagnostic and therapeutic challenges.
Dinç UA; Yenerel NM; Görgün E; Yetik H; Kokame GT; Lim JI
Retina; 2009 Feb; 29(2):275-9. PubMed ID: 18827730
[No Abstract] [Full Text] [Related]
12. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.
Saito W; Kase S; Ohgami K; Mori S; Ohno S
Acta Ophthalmol; 2010 May; 88(3):377-80. PubMed ID: 18778334
[TBL] [Abstract][Full Text] [Related]
15. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
Kumar V; Ghosh B; Raina UK; Goel N
Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
[No Abstract] [Full Text] [Related]
16. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab in postoperative pseudophakic cystoid macular edema: does it really work?
Spitzer MS; Szurman P; Bartz-Schmidt KU
J Cataract Refract Surg; 2008 Jun; 34(6):880; author reply 880-1. PubMed ID: 18498977
[No Abstract] [Full Text] [Related]
18. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
Meyerle CB; Freund KB; Iturralde D; Spaide RF; Sorenson JA; Slakter JS; Klancnik JM; Fisher YL; Cooney MJ; Yannuzzi LA
Retina; 2007; 27(4):451-7. PubMed ID: 17420697
[TBL] [Abstract][Full Text] [Related]
20. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema.
Barone A; Russo V; Prascina F; Delle Noci N
Retina; 2009 Jan; 29(1):33-7. PubMed ID: 18854783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]